What is the ONPATTRO SmPC (summary of product characteristics) for?
ONPATTRO’s SmPC is the official European product document that explains how the medicine should be prescribed and used. It covers the approved indications, dosing, method of administration, contraindications, warnings/precautions, interactions, pregnancy and lactation information, adverse reactions, and key pharmacology details.
What does the SmPC include for prescribing ONPATTRO?
In practice, prescribers use the ONPATTRO SmPC to find details such as:
- Approved use (including the patient population the product is indicated for)
- Dosing schedule and dose adjustments
- How ONPATTRO should be administered (including any premedication and monitoring instructions described in the SmPC)
- Contraindications (when it must not be used)
- Warnings and precautions (including any risks the SmPC highlights)
- Adverse reactions reported for the product
- Interactions with other medicines
- Use in special populations (renal/hepatic impairment, pregnancy, breastfeeding, pediatrics/older adults—where stated)
How can I find the exact ONPATTRO SmPC document?
The fastest way is to search for the “ONPATTRO SmPC” on your country’s medicines regulator site (often the EMA-hosted product page for EU approvals). If you tell me which country/region you’re in (EU/UK or a specific country), I can point you to the most relevant official SmPC link.
Why the SmPC matters for patients and clinicians
Clinicians rely on the SmPC for safety and correct use, including instructions related to infusion procedures and monitoring, while patients and carers often use it to understand risks and what to watch for.
Patent and market context (if you’re researching availability)
If your goal is also to understand ONPATTRO’s commercial/market status (e.g., exclusivity and patents), DrugPatentWatch.com is a useful starting point for tracking patent information for ONPATTRO: DrugPatentWatch.com.
Sources